Renal Diseases Market Trends, Demand & Growth by 2034

Coverage: By Disease Type ( Chronic Kidney Disease, End-Stage Renal Disease (ESRD), Acute Kidney Disease ); Treatment Type ( Dialysis, Medication, Kidney Transplantation, Surgery, Diet, Others ); Diagnosis ( Blood tests, Imaging Tests, Biopsy, Urine tests, Others ); End User ( Dialysis Centers, Hospital and Clinics, Research and Academic Institutes ), and Geography (North America, Europe, Asia Pacific, and South and Central America)

Historic Data: 2021-2024 | Base Year: 2025 | Forecast Period: 2026-2034
  • Status : Data Released
  • Report Code : TIPRE00017692
  • Category : Life Sciences
  • No. of Pages : 150
  • Available Report Formats : pdf-format excel-format
  • Last update date : April 17, 2026
Renal Diseases Market Trends, Demand & Growth by 2034
Report Date: April 17, 2026   |   Report Code: TIPRE00017692 Email: sales@theinsightpartners.com

2025 Market Size

US$ 135.35 Bn

Base year value

2034 Forecast

US$ 267.48 Bn

Projected by 2034

CAGR 2026-2034

7.86 %

Growth rate

Addressable Market

US$ 1,812.42 Bn

(2026-2034)

The global renal diseases market size is projected to reach US$ 267.48 billion by 2034 from US$ 135.35 billion in 2025. The market is anticipated to register a CAGR of 7.86% during the forecast period 2026-2034.

The report is segmented by Disease Type (Chronic Kidney Disease, End-Stage Renal Disease (ESRD), Acute Kidney Disease); Treatment Type (Dialysis, Medication, Kidney Transplantation, Surgery, Diet, Others); Diagnosis (Blood tests, Imaging Tests, Biopsy, Urine tests, Others) and End User (Dialysis Centers, Hospital and Clinics, Research and Academic Institutes). The global analysis is broken down at the regional level and for major countries. The market evaluation is presented in US$ for the above segmental analysis.


Market Research Highlights

  • Global market for Renal Diseases was valued at US$ 135.35 Billion in 2025
  • Annual market size is expected to reach US$ 267.48 Billion by 2034
  • Total addressable market (TAM) during 2026-2034 is projected to reach approximately US$ 1,812.42 Billion
  • Market is anticipated to register a CAGR of 7.86% during the forecast period
  • The United States represents a key market, supported by Increasing Prevalence of Chronic Kidney Disease (CKD), Advances in Dialysis Technologies, Growing Awareness and Early Detection of Kidney Disease, as well as evolving industry dynamics
  • Market analysis covers North America, Europe, Asia-Pacific, South and Central America, Middle East and Africa, with growth evaluated across the forecast period
  • Market opportunities such as Targeted therapies and Novel Drug Therapy, Expanding Kidney Transplantation Programs, Innovations in Kidney Transplantation and Organ Preservation Technologies are expected to influence market dynamics and addressable market
  • Report profiles industry participants, including Abbott, , Amgen Inc., AstraZeneca, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Novartis AG, Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., while analyzing competitive strategies and innovation developments
  • Source: The Insight Partners' analysis based on proprietary research, government publications, company annual reports, investor presentations, industry databases, and expert interviews.

● REPORT CUSTOMIZATION

Tailor This Report To Align With Your Specific Business Requirements

This report can be customized to align precisely with your business objectives, scope, and target markets. Customization options include tailored segmentation, geography, competitive analysis, and strategic insights to support informed decision-making.

Customize This Report →

WHAT YOU CAN ADJUST

  • Segmentations
  • Geography
  • Competitive Analysis
  • Language Preferences

Renal Diseases Market: Strategic Insights

renal-diseases-market
  • Get Top Key Market Trends of this report.
    This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Purpose of the Report


The report Renal Diseases Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:



  1. Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
  2. Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
  3. Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.

Renal Diseases Market Segmentation Disease Type



  1. Chronic Kidney Disease
  2. End-Stage Renal Disease
  3. Acute Kidney Disease

Treatment Type



  1. Dialysis
  2. Medication
  3. Kidney Transplantation
  4. Surgery
  5. Diet

Diagnosis



  1. Blood tests
  2. Imaging Tests
  3. Biopsy
  4. Urine tests

End User



  1. Dialysis Centers
  2. Hospital and Clinics
  3. Research and Academic Institutes

Renal Diseases Market Report Scope

Report Attribute Details
Market size in 2025 US$ 135.35 Billion
Market Size by 2034 US$ 267.48 Billion
Global CAGR (2026 - 2034) 7.86%
Historical Data 2021-2024
Forecast period 2026-2034
Segments Covered By Disease Type
  • Chronic Kidney Disease
  • End-Stage Renal Disease
  • Acute Kidney Disease
By Treatment Type
  • Dialysis
  • Medication
  • Kidney Transplantation
  • Surgery
  • Diet
By Diagnosis
  • Blood tests
  • Imaging Tests
  • Biopsy
  • Urine tests
By End User
  • Dialysis Centers
  • Hospital and Clinics
  • Research and Academic Institutes
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Abbott, 
  • Amgen Inc.
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.

Renal Diseases Market Players Density: Understanding Its Impact on Business Dynamics

The Renal Diseases Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

renal-diseases-market-cagr



Renal Diseases Market Growth Drivers



  1. Increasing Prevalence of Chronic Kidney Disease (CKD): The rising prevalence of chronic kidney disease (CKD) is one of the most significant growth drivers for the renal diseases market. Kidney-related disorders including CKD are becoming more common as people around the world grow older. The leading factors of CKD include diabetes and hypertension together with obesity which are both rising in global prevalence. The World Health Organization (WHO) now considers CKD an urgent public health challenge because it leads to several fatal complications like cardiovascular disease. While developed countries see growing CKD rates in aging populations developed nations witness higher CKD cases among older people while developing regions experience kidney disease spikes due to rising diabetes and hypertension cases. Early detection and management of CKD helps slow disease progression which creates higher demand for renal disease treatments and monitoring solutions. The renal diseases market is experiencing significant growth because healthcare systems are now emphasizing early diagnosis along with individualized treatment methods to enhance patient outcomes. Non-invasive diagnostic methods like biomarker tests and imaging help detect kidney problems earlier which boosts demand for pharmaceuticals and treatments targeting kidney function and management. The renal diseases market growth is anticipated because CKD global prevalence keeps increasing which creates more demand for dialysis services, renal transplantation, and medications for kidney diseases.
  2. Advances in Dialysis Technologies: Developments in dialysis technologies act as a vital growth factor for the market addressing renal diseases. Hemodialysis and peritoneal dialysis stand as fundamental treatments for patients suffering from end-stage renal disease (ESRD). As more CKD patients advance to ESRD the requirement for dialysis services and products continues to expand. New technologies in dialysis machines and procedures have led to better patient results while shortening dialysis treatment times and improving patient comfort during process.


Frequently Asked Questions

The Renal Diseases Market is growing at a CAGR of 7.86% from 2026 to 2034

The major factors driving the Renal Diseases Market are Increasing Prevalence of Chronic Kidney Disease (CKD), Advances in Dialysis Technologies, and Growing Awareness and Early Detection of Kidney Disease.

Future trends in the Renal Diseases Market are Growing Focus on Preventative Care and Early Intervention, Increased Adoption of Telemedicine in Renal Disease Management, and Growth of Home-Based Dialysis Solutions.

Some of the players operating in the market are Abbott, Amgen Inc., AstraZeneca, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC,Novartis AG, Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd.

The report can be delivered in PDF/PPT format; we can also share an excel datasheet based on the request.

Some customization options available based on the request are an additional 3-5 company profiles and a country-specific analysis of 3-5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation# as our team would review the same and check the feasibility.
Mrinal Kerhalkar
Manager,
Market Research & Consulting

Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.

Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.

  • Comprehensive Market Sizing and Forecast Analysis
  • Detailed Segmentation Analysis
  • In-Depth Market Dynamics Assessment
  • Regional and Country-Level Insights
  • Competitive Landscape and Company Benchmarking
  • Strategic Business Intelligence

Testimonials

Reason to Buy

  • Informed Decision-Making
  • Understanding Market Dynamics
  • Competitive Analysis
  • Identifying Emerging Markets
  • Customer Insights
  • Market Forecasts
  • Risk Mitigation
  • Boosting Operational Efficiency
  • Strategic Planning
  • Investment Justification
  • Tracking Industry Innovations
  • Aligning with Regulatory Trends
Sales Assistance
US: +1-646-491-9876
UK: +44-20-8125-4005
DUNS Logo
ISO Certified Logo
GDPR
CCPA